May 13, 2020
Telehealth and online medical services have accorded many opportunities for healthcare professionals and patients around the world. A larger section of society is leveraging online medical services for the treatment, diagnosis, and monitoring of diseases. Due to Covid-19, online health services have registered ...
Read More...
May 12, 2020
MyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Following the announcement, shares of the California-based company skyrocketed. The Phase III clinical trial - EXPLORER-HCM – demonstrated the pot...
Read More...
May 11, 2020
Several promising new developments and novel treatment approaches are fuelling Huntington’s disease Market. Progressive neurological disorders such as Parkinson disease (PD), motor neuron disease (MND), Huntington disease (HD), or multiple sclerosis (MS), despite the advent of technological advances in healthc...
Read More...
May 08, 2020
The current Beta-thalassemia market is experiencing the emergence of gene therapies as a one-time cure for the patients. Beta thalassemia is relatively a common heterogeneous autosomal recessive hereditary blood disorder. It is a common form of hemoglobinopathy characterized by ineffective erythropoiesis leadi...
Read More...
May 07, 2020
Avrobio taps ADC of Magenta for enhancing gene therapy conditioning Avrobio is working to make conditioning safer. The company is collaborating with Magenta Therapeutics to check antibody-drug conjugate. Under the agreement, the partners will evaluate Magenta’s lead conditioning program, MGTA-117, with at lea...
Read More...
May 06, 2020
The Worldwide situation due to novel coronavirus since its outbreak in china is getting worse with each passing day. To flatten the curve, countries around the world have adopted various unprecedented measures. The shutdown and social distancing have slowed down the rate of infection to a larger extent but...
Read More...
May 05, 2020
Florence-based Menarini Group has announced a USD667 million acquisition of the Stemline Therapeutics, an oncology-focused company. As per the agreement, Menarini plans to help Stemline to build a strong foothold in the U.S., and will also continue the development of Elzonris, a CD123 targeted therapy. Th...
Read More...
May 04, 2020
Many players such as Immunogen, On Target Laboratories, ImmunoVaccine Technologies, OncoQuest, Precigen, and some others are involved in developing therapies to accelerate the Ovarian Cancer Market. Cancer, coronary heart disease, and stroke are the leading contributors of the mortality worldwide, estimated ...
Read More...
Nov 29, 2024
Lung cancer, to date, remains the leading cause of death worldwide, however, the epidemiological analysis depicts varying NSCLC incidence all over the world. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. The number of people living for at least five years after ...
Read More...
Apr 30, 2020
Remdesivir of Gilead accelerates COVID-19 recovery Gilead Sciences' Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized COVID-19 patients by four days or 31% as published in a National Institutes of Health-sponsored study setting the drug against p...
Read More...